Cell cycle checkpoint in cancer: A therapeutically targetable double-edged sword

253Citations
Citations of this article
455Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Major currently used anticancer therapeutics either directly damage DNA or target and upset basic cell division mechanisms like DNA replication and chromosome segregation. These insults elicit activation of cell cycle checkpoints, safeguard mechanisms that cells implement to correctly complete cell cycle phases, repair damage or eventually commit suicide in case damage is unrepairable. Although cancer cells appear to be advantageously defective in some aspects of checkpoint physiology, recent acquisitions on the biochemical mechanisms of the various checkpoints are offering new therapeutic approaches against cancer. Indeed, chemical manipulation of these mechanisms is providing new therapeutic strategies and tools to increase the killing efficacy of major cancer therapeutics as well as to directly promote cancer cell death. In this review we summarize developing concepts on how targeting cell cycle checkpoints may provide substantial improvement to cancer therapy.

Cite

CITATION STYLE

APA

Visconti, R., Della Monica, R., & Grieco, D. (2016, September 27). Cell cycle checkpoint in cancer: A therapeutically targetable double-edged sword. Journal of Experimental and Clinical Cancer Research. BioMed Central Ltd. https://doi.org/10.1186/s13046-016-0433-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free